Fortress Biotech (NASDAQ:FBIO) Receives FDA Approval for UNLOXCYT™ for Treatment of cSCCOn December 13, 2024, Fortress Biotech, Inc. released an 8-K filing announcing a significant development for its majority-controlled subsidiary, Checkpoint Therap
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Fortress Biotech’s 8K filing here. About Fortress Biotech (Get Free Report) Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, […]
More Stories
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)
Investment analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Get Free Report) in a research report issued...
NortonLifeLock (NASDAQ:NLOK) Coverage Initiated at StockNews.com
Research analysts at StockNews.com started coverage on shares of NortonLifeLock (NASDAQ:NLOK – Get Free Report) in a research note issued...
CVD Equipment (NASDAQ:CVV) Earns Hold Rating from Analysts at StockNews.com
Equities research analysts at StockNews.com assumed coverage on shares of CVD Equipment (NASDAQ:CVV – Get Free Report) in a report...
Short Interest in IsoEnergy Ltd. (OTCMKTS:ISENF) Increases By 22.0%
IsoEnergy Ltd. (OTCMKTS:ISENF – Get Free Report) was the target of a significant growth in short interest during the month...
International Tower Hill Mines (NYSE:THM) Now Covered by StockNews.com
StockNews.com assumed coverage on shares of International Tower Hill Mines (NYSE:THM – Free Report) in a report published on Saturday....
Alpha Capital Acquisition’s (OTCMKTS:ASPCU) Quiet Period Will Expire Tomorrow
Alpha Capital Acquisition’s (OTCMKTS:ASPCU – Get Free Report) quiet period will expire on Wednesday, December 18th. Alpha Capital Acquisition had...